(Q38322827)

2 September 2017

1 reference

title

Quinolone antimicrobial agents: adverse effects and bacterial resistance (English)

1 reference

2 September 2017

0 references

J S Wolfson

1

1 reference

2 September 2017

publication date

1 December 1989

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

2 September 2017

published in

1 reference

2 September 2017

volume

8

1 reference

2 September 2017

issue

12

1 reference

2 September 2017

page(s)

1080-1092

1 reference

Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Inhibitory effect of cephalosporins on gamma-aminobutyric acid receptor binding in rat synaptic membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

The influence of quinolone derivatives on theophylline clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Effect of norfloxacin on theophylline pharmacokinetics at steady state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Treatment of uncomplicated gonorrhea with rosoxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Rosoxacin in the therapy of uncomplicated gonorrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Ciprofloxacin and allergic interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Sucralfate reduces the gastrointestinal absorption of norfloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Norfloxacin: a new targeted fluoroquinolone antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Norfloxacin disposition after sequentially increasing oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

No cytogenetic effects of quinolone treatment in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Mode of Incomplete Cross-Resistance Among Pipemidic, Piromidic, and Nalidixic Acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Accumulation of enoxacin by Escherichia coli and Bacillus subtilis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Endogenous active efflux of norfloxacin in susceptible Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Inhibition of conjugal transfer of R plasmids by pipemidic acid and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Elimination of plasmids by new 4-quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Mutation of Salmonella paratyphi A conferring cross-resistance to several groups of antibiotics by decreased permeability and loss of invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Norfloxacin resistance in a clinical isolate of Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

The new quinolones and their combinations with other agents for therapy of severe infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

In vitro antistaphylococcal activity of pefloxacin alone and in combination with other antistaphylococcal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01975175

Ciprofloxacin and antacids

21 January 2018

1 reference

12 December 2020

Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group

1 reference

12 December 2020

Serum and sputum concentrations of enoxacin after single oral dosing in a clinical and bacteriological study

1 reference

12 December 2020

Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.

1 reference

12 December 2020

Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases

1 reference

12 December 2020

Ofloxacin and antacids

1 reference

12 December 2020

Clinical experience with ciprofloxacin in the USA.

1 reference

12 December 2020

Reduced enteral absorption of ciprofloxacin in the presence of antacids

1 reference

12 December 2020

Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods

1 reference

12 December 2020

Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization

1 reference

12 December 2020

Inactivation of quinolone by feces

1 reference

12 December 2020

Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

1 reference

12 December 2020

Convulsions related to enoxacin

1 reference

12 December 2020

Pefloxacin in acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Resistance to ciprofloxacin.

1 reference

12 December 2020

Enterococcal superinfection in patients treated with ciprofloxacin

1 reference

12 December 2020

Ciprofloxacin and tenosynovitis

1 reference

12 December 2020

1 reference

12 December 2020

The subcorneal pustular drug eruption: an example induced by norfloxacin

1 reference

12 December 2020

Ciprofloxacin therapy in cystic fibrosis

1 reference

12 December 2020

Arthropathy in a patient with cystic fibrosis taking ciprofloxacin

1 reference

12 December 2020

Economic impact of oral ciprofloxacin. A pharmacist's perspective.

1 reference

12 December 2020

A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections.

1 reference

12 December 2020

Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections

1 reference

12 December 2020

Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme

1 reference

12 December 2020

The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo

1 reference

12 December 2020

Frequency and expression of mutational resistance to the 4-quinolone antibacterials

1 reference

12 December 2020

Gyrase-inhibitors impair caffeine elimination in man

1 reference

12 December 2020

Norfloxacin-induced rheumatic disease.

1 reference

12 December 2020

Development of resistance during antibiotic therapy

1 reference

12 December 2020

Ciprofloxacin versus cinoxacin in therapy of urinary tract infections. A randomized, double-blind trial.

1 reference

12 December 2020

In vitro emergence ofEscherichia coli andPseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid

1 reference

12 December 2020

Cloning and sequencing of the Escherichia coli gyrA gene coding for the A subunit of DNA gyrase

1 reference

12 December 2020

Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.

1 reference

12 December 2020

Crystalluria and ciprofloxacin, influence of urinary pH and hydration

1 reference

12 December 2020

Norfloxacin: review of safety studies

1 reference

12 December 2020

Drug interactions of ciprofloxacin with other non-antibiotic agents

1 reference

12 December 2020

New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

1 reference

12 December 2020

Treatment of urinary tract infection with norfloxacin. Analysis of cost

1 reference

12 December 2020

Efficacy of ofloxacin in the treatment of lower respiratory tract infections in general practice.

1 reference

12 December 2020

New synthetic quinolone antibacterial agents and serum concentration of theophylline

1 reference

12 December 2020

Ciprofloxacin-induced hematuria

1 reference

12 December 2020

Norfloxacin versus placebo for prophylaxis against travellers' diarrhoea

1 reference

12 December 2020

Treatment failure of ofloxacin in Campylobacter pylori infection

1 reference

12 December 2020

Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis

1 reference

12 December 2020

Plasmid-mediated resistance to nalidixic acid in Shigella dysenteriae type 1.

1 reference

12 December 2020

Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis.

1 reference

12 December 2020

Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli

1 reference

12 December 2020

R-plasmid transfer and its response to nalidixic acid

1 reference

12 December 2020

Economic impact of streamlining antibiotic administration

1 reference

12 December 2020

Ciprofloxacin in the treatment of acute bacterial diarrhea: a double blind study

1 reference

12 December 2020

1 reference

12 December 2020

World-wide clinical experience with norfloxacin: efficacy and safety

1 reference

12 December 2020

Specific toxicologic aspects of the quinolones.

1 reference

12 December 2020

Case report of renal failure during norfloxacin therapy

1 reference

12 December 2020

Resistance of Neisseria gonorrhoeae to enoxacin.

1 reference

12 December 2020

Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity

1 reference

12 December 2020

The tolerability profile of prophylactic norfloxacin in neutropenic patients

1 reference

12 December 2020

Ciprofloxacin: an update on clinical experience.

1 reference

12 December 2020

Norfloxacin in the treatment of urinary tract infections in men with and without identifiable urologic complications.

1 reference

12 December 2020

Mapping the active site tyrosine of Escherichia coli DNA gyrase

1 reference

12 December 2020

Molecular basis of bacterial outer membrane permeability

1 reference

12 December 2020

DNA gyrase (Topoisomerase II) from Pseudomonas aeruginosa.

1 reference

12 December 2020

Ciprofloxacin and antacids

1 reference

12 December 2020

Quinolone-resistant mutations of the gyrA gene of Escherichia coli

1 reference

12 December 2020

Combination therapy: a way to limit emergence of resistance?

1 reference

12 December 2020

Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections.

1 reference

12 December 2020

Corynebacterium jeikeium (group JK) resistance to ciprofloxacin emerging during therapy

1 reference

12 December 2020

Interaction of gentamicin, dibekacin, netilmicin and amikacin with various penicillins, cephalosporins, minocycline and new fluoro-quinolones against Enterobacteriaceae and Pseudomonas aeruginosa

1 reference

12 December 2020

Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

1 reference

12 December 2020

Pharmacologic studies with 7-benzyl-1-ethyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid

1 reference

12 December 2020

Safety of ofloxacin--adverse drug reactions reported during phase-II studies in Europe and in Japan

1 reference

12 December 2020

Adverse effects of the fluoroquinolones.

1 reference

12 December 2020

[Effect of pH value and magnesium on the antibacterial activity of quinolone preparations]

1 reference

12 December 2020

Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women

1 reference

12 December 2020

Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.

1 reference

12 December 2020

Oral ciprofloxacin therapy of infection caused by multiply resistant bacteria other than Pseudomonas aeruginosa

1 reference

12 December 2020

TolF locus in Escherichia coli: chromosomal location and relationship to loci cmlB and tolD

1 reference

12 December 2020

Drug interactions with quinolones

1 reference

12 December 2020

Treatment of nongonococcal urethritis with ciprofloxacin

1 reference

12 December 2020

Emergence of ofloxacin-resistant Citrobacter freundii and Pseudomonas maltophilia after ofloxacin therapy.

1 reference

12 December 2020

Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine

1 reference

12 December 2020

Escherichia coli K-12 Mutants Resistant to Nalidixic Acid: Genetic Mapping and Dominance Studies

1 reference

12 December 2020

Overview of postmarketing experience with ofloxacin in Germany

1 reference

12 December 2020

Apparent absence of transferable resistance to nalidixic acid in pathogenic Gram-negative bacteria

1 reference

12 December 2020

Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days

1 reference

12 December 2020

Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant

1 reference

12 December 2020

Safety profile of ofloxacin: the Italian data base

1 reference

12 December 2020

Mechanisms of action of and resistance to ciprofloxacin

1 reference

12 December 2020

Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial

1 reference

12 December 2020

Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa

1 reference

12 December 2020

Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections

1 reference

12 December 2020

Possible interaction of ciprofloxacin with cyclosporin A

1 reference

12 December 2020

Norfloxacin (Noroxin)

1 reference

12 December 2020

Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients

1 reference

12 December 2020

Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli

1 reference

12 December 2020

Oral norfloxacin versus parenteral treatment of nosocomial urinary tract infection.

1 reference

12 December 2020

Norfloxacin versus co-trimoxazole for treatment of urinary tract infections in adults: microbiological results of a coordinated multicentre study.

1 reference

12 December 2020

Ciprofloxacin: an overview of adverse experiences

1 reference

12 December 2020

1 reference

12 December 2020

The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.

1 reference

12 December 2020

Multiclinic study of norfloxacin for treatment of urinary tract infections

1 reference

12 December 2020

Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract

1 reference

12 December 2020

Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity

1 reference

12 December 2020

Oral ciprofloxacin in resistant urinary tract infections

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01975175

1 reference

Dimensions Publication ID

2 September 2017

1013851352

0 references

1 reference